TrialThe oncologist2023

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.

Sri Harsha Tella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.